KLRK1 and acute myeloid leukemia: These in vitro and in vivo data suggest that gilteritinib may promote the antileukaemic activities of FLT3scFv/NKG2D-CAR T cells by upregulating NKG2DL and FLT3 expression in AML cells, which enhances the AML targeting efficiency of CAR T cells.